imageStock Markets18 minutes ago (Aug 05, 2020 07:35AM ET)

(C) Reuters.

(Reuters) – Regeneron Pharmaceuticals Inc (O:REGN) beat second-quarter profit estimates on Wednesday, spurred by higher sales of its blockbuster eczema treatment Dupixent, and higher revenues connected to its collaboration with Sanofi SA (PA:SASY) and Bayer AG (DE:BAYGn).

Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron’s blockbuster drug Eylea.

Sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.75 billion from $1.88 billion. This was offset by a nearly 70% jump in sales of Dupixent, made in collaboration with Sanofi.

Net income rose to $897.3 million, or $7.61 per share, in the second quarter ended June 30, from $193.1 million, or $1.68 per share, a year earlier. The company recorded a $228 million gain related to the sale of equity and debt securities in the reported quarter.

On an adjusted basis, the company earned $7.16 per share, handily beating estimates of $5.98, according to Refinitiv IBES data.

Revenue rose 23.7% to $1.95 billion, higher than estimates of $1.74 billion.

Regeneron profit beats on Dupixent strength

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

LEAVE A REPLY

Please enter your comment!
Please enter your name here